



July 16, 2010

R. Sanders Williams, MD
Dean, University School of Medicine
Vice Chancellor for Academic Affairs
Duke University Medical Center
Suite 1103 Hock Plaza, Box 2772
242 Erwin Road
Durham, NC 27710

Dear Dr. Williams:

RE: Grant # MRSR-07-107-01-CCE

We have recently become aware that Dr. Anil Potti of your institution submitted a Mentored Research Scholar grant application in October 2006, to the American Cancer Society that may have incorrect biographical information about him. The application was judged worthy of funding and a grant was awarded to Duke University in the amount of \$729,000 for the period July 1, 2007 through June 30, 2012.

We are extremely concerned about these allegations as we take accuracy in the scientific process very seriously. We ask that you provide us with an official curriculum vitae for Dr. Potti and an explanation of any variance it may have from the one included in his grant application (copy attached). We are also interested in what action you are taking to assure that the funded work has been done to the highest standards of science, accuracy and integrity. Payments on the grant are being withheld until these issues are satisfactorily resolved.

We look forward to hearing your response as soon as possible.

Sincerely,

A handwritten signature in cursive script that reads "David Ringer".

David Ringer, PhD, MPH
Vice President for Extramural Grants

cc: Otis Brawley, MD
Greg Donaldson
Sheffield Hale
Margaret Offermann, MD, PhD

Enclosure

stay well | get well | find cures | fight back | advance | 1-800-237-2343

National Home Office
250 Williams Street Atlanta, GA 30303-1002

BIOGRAPHICAL INFORMATION OF APPLICANT

(Do not exceed two pages for total biographical information.)

Last name, First name: Potti, Anil			
Education			
Degree/Year Conferred	Institution/Location	Field of Study	
M.D./1995	Christian Medical College and Hospital Vellore, India.	Medicine	
Training			
Title	Mentor	Institution	Dates
Research Fellowship	Gordon McLaren	Queensland Research Institute Australia	1995-96
Residency	James Hanley	UND School of Medicine USA	1996-2000
Oncology Fellowship	Joe Nevins and Jeffrey Crawford	Duke University USA	2003-2006
Appointments			
Title	Institution		Dates
Chief Resident	UND School of Medicine		2000-2001
Asst. Professor	UND School of Medicine (J-1 visa waiver)		2001-2003
Asst. Professor	Duke University Medical Center		2006 -
Justification of Eligibility (if appropriate)			
I am currently a permanent resident of the United States and have accepted a position as an Assistant Professor at Duke University starting June 2006.			
Eligibility Status			
Year last degree conferred:		1995 (M.D.); 2006 (Oncology fellowship)	
Year of first independent position:		June/July 2006 * enter date in appropriate box on Title page	

HONORS AND AWARDS

- 1989 National Merit Scholar.
- 1995 Best Outgoing House Officer (Medical School).
- 1995 Rhodes Scholar (Australia).
- 1997 Outstanding Resident of the Year.
- 1997 Resident Teacher of the Year.
- 1998 American Society of Clinical Oncology (ASCO) Merit Award.
- 1998 Young Investigator Award - AFMR/CSCR.
- 1998 Research Competition Winner at the Annual ACP Scientific Meeting.
- 1999 Alpha-Omega-Alpha (**AOA**) Honor Society Membership.

BIOGRAPHICAL INFORMATION OF APPLICANT

- 2000 UND Academic & Teaching Excellence Award.
- 2001 Young Investigator Award - Central Society of Clinical Research (CSCR)
- 2002 Golden Apple Award (teaching award from medical students).
- 2003 Leonard P. Tow Humanism in Medicine Award.
- 2003 Golden Apple Award (teaching award from medical students).
- 2003 Frank N. Low Prize in Clinical Research.
- 2004 Claus Strohlein Lung Cancer Research Award.
- 2004 American Society of Hematology (ASH) Clinical Research Scholar
- 2005 ASCO/Aventis Fellows Oncology Award.
- 2005 Duke Scholar in Genomic Medicine.
- 2006 Robert Silber Research Prize in Oncology.
- 2006 Barbara Bell Award for Research Excellence in Basic Biomedical Sciences.

PUBLICATIONS (if partial list is given, indicate total number of publications): (selected from over 55 publications)

1. **Potti A**, Mukherjee S, Petersen R, Dressman HK, Bild A, Kratzke R, Watson M, Kelley MJ, Ginsburg G, West M, Harpole D, Nevins JR. A Genomic Strategy to Refine Prognosis and Therapeutic Decision for Adjuvant Therapy in Non-Small Cell Lung Carcinoma. *New Engl J Med*, 2006, 355, 570-580.
2. **Potti A**, Dressman HK, Bild A, Riedel R, Lancaster J, Berchuk A, Kelley M, Ginsberg G, Nevins JR, Febbo PG. A genomic approach to combinatorial therapeutics in solid tumors. *Nature Medicine*, in press.
3. Bild A, **Potti A**, Nevins JR. Linking Oncogenic Pathways to Targeted Therapies. *Nature Reviews Cancer*, (epub) July 2006.
4. **Potti A**, Ganti AK. Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future. *Expert Opin Biol Ther*. 2006 Jul;6(7):709-16.
5. Bild A, Yao G, Chang JT, **Potti A**, Chasse D, Harpole D, Lancaster JL, Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR. Signatures of Oncogenic Pathway Deregulation in Human Cancers as a Guide to Targeted Therapeutics. *Nature*. Nov 2005 (epub).
6. Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar K, **Potti A**. Hormone replacement therapy is associated with decreased survival in women with lung cancer. *J Clin Oncol*. 2005;24(1):59-63.
7. **Potti A**, Bild A, Dressman H, Lewis DA, Nevins JR, Ortel TL. Gene expression patterns predict phenotypes of immune mediated thrombosis. *Blood*. 2006;107(4):1391-6.
8. Ganti AK, **Potti A**. Epidermal growth factor inhibition in solid tumours. *Expert Opin Biol Ther*. 2005 Sep;5(9):1165-1174.
9. **Potti A**, Ganti AK, Tuchman SA, Sholes K, Langness E, Koka V, Koch M. HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC). *J Carcinog*. 2005;4(1):8
10. Patel P, Henry LL, Ganti AK, **Potti A**. Clinical course of lung cancer in patients with chronic kidney disease. *Lung Cancer*. 2004;43(3):297-300.
11. **Potti A**, George DJ. Tyrosine kinase inhibitors in renal cell carcinoma. *Clin Cancer Res*. 2004 (2):6371-6.
12. Chen G, Shukeir N, **Potti A**, Sircar K, Aprikian A, Goltzman D, Rabbani SA. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. *Cancer*. 2004;101(6):1345-56.
13. **Potti A**, Ganti AK, Sholes K, Langness E, Koka V, Horvarth L, Koch M. Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma. *Clin Cancer Res*. 2003;9(13):4872-6.
14. **Potti A**, Moazzam N, Ramar K, Hanekom DS, Kargas S, Koch M. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. *Ann Oncol*. 2003;14(6):894-7.
15. **Potti A**, Willardson J, Forseen C, Kishor Ganti A, Koch M, Hebert B, Levitt R, Mehdi SA. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. *Lung Cancer*. 2002;36(3):257-61.
16. **Potti A**, Abdel-Raheem M, Levitt R, Schell DA, Mehdi SA. Intramedullary spinal cord metastases (ISCM) and non-small cell lung carcinoma (NSCLC): clinical patterns, diagnosis and therapeutic considerations. *Lung Cancer*. 2001;31(2-3):319-23.